Opendata, web and dolomites

ANAPRINT

Additive Printing for Cell-based Analysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ANAPRINT project word cloud

Explore the words cloud of the ANAPRINT project. It provides you a very rough idea of what is the project "ANAPRINT" about.

disruptive    plan    global    functional    forecast    15    multiple    se    successful    extend    core    whilst    market    drugs    hepatotoxicity    ipsc    human    partnership    client    planning    extension    decisions    ip    leaders    scalable    budget    asia    ranging    industry    trl7    trl9    printed    assay    prototype    strategic    alone    national    platform    ready    hepatocytes    marketed    manufacturing    uk    win    models    data    skills       5m    arising    efficiencies    automating    initial    confidence    culture    innovation    additive    assays    consistent    cell    integration    party    producing    2016    printing    sectors    advantage    assembly    volume    moved       companies    opinion    2bn    japan    12    audit    predictive    competitive    specialist    share    pricing    materials    prototypes    services    screening    cagr    commercialise    6m    markets    business    financial    post    reactive    healthcare    sales    centre    operations    positive    expanding    acs    distributors    jv    foods    launch    remote    commercial    aided    beta    sold   

Project "ANAPRINT" data sheet

The following table provides information about the project.

Coordinator
AvantiCell Science Ltd 

Organization address
address: GIBBSYARD BUILDING
city: AYR
postcode: KA6 5HW
website: www.avanticell.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.avanticell.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-10-01   to  2015-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AvantiCell Science Ltd UK (AYR) coordinator 50˙000.00

Map

 Project objective

The Project will develop and commercialise the additive printing of cell-based analysis systems. The objective is to deliver consistent, scalable manufacturing of cell-based models used by multiple industry sectors to evaluate materials ranging from new drugs to healthcare products and functional foods. The target market is global and growing (CAGR 12%; estimated $4.2Bn in 2016). Additive printing will have positive disruptive impact, automating assay assembly and producing complex models needed by industry to improve the predictive value of cell-based analysis. Operational efficiencies and competitive pricing of printed cell products and services will win market share by making high-end analysis available to non-specialist users, whilst allowing wider integration of complex models into high-volume screening. The market advantage will be cost-effective testing and greater confidence in commercial decisions with strategic and financial impact. The Phase 1 business plan will be built on market data, IP/technology audit and financial planning arising from 8 years’ successful ACS cell-based business. Phase 1 shall also prototype assays printed with iPSC-derived hepatocytes aimed at high-value hepatotoxicity testing; prototypes will be moved to TRL7, and in Phase 2 to market-ready TRL9 with client-reactive design aided by beta testing with opinion leaders. Technical innovation will use ACS core skills in human cell culture and build on commercial partnership with the UK National Centre for Additive Printing. Phase 2 will extend the technology platform to other cell models, expanding product range and commercial value. Post-project, these will be marketed and sold by expanding existing operations: initial hepatotoxicity sales alone are forecast at €0.6M one year post-launch (0.15% of global market). Market/sales extension to remote markets e.g. SE Asia will use JV companies or third-party distributors e.g. Japan. The Project requires 2.5 years and a budget of €2-2.5M.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANAPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ANAPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More  

NANOHIGH (2015)

High volume production facility for high accuracy nanocapsules

Read More  

WORKSHOP4.0 (2016)

Automated real-time production forecasting for industry

Read More